Tanya Wildes MD Profile picture
Heme/onc/geriatrician @UNMC @NebraskaMedicine studying Myeloma & other cancers + Aging. Training for Peru Trek: https://t.co/wI3oswKkxL
Sep 23, 2020 12 tweets 5 min read
I have done the academically unfathomable:

I am resigning my faculty position without another job lined up. While I am 100% confident in my decision, I am also 100% sad.

This did not have to happen. #womeninmedicine 1/ I am not burned out. I love what I do. I love my patients and I love my research. I am not quitting my calling. I am being brave enough to be CEO of my own life. @RUBraveEnough 2/
Dec 9, 2019 5 tweets 3 min read
Abs 694: Dr Puiz presents GEM-Claridex trial of Rd vs Clarithromycin-RD. Got to witness Sweet moment at end when her mentor @mvmateos flashed her the “Great job, my protege!” smile we all need to see ❤️ ImageImage GEM-Clarieex provides another cautionary tale about a myeloma regimen that is more effective but more toxic in older patients #geriheme....
Dec 8, 2019 6 tweets 4 min read
Blown away by rising star @mwschoen's masterful storytelling of how he is trying to understand and eradicate racial disparities in myeloma treatment and outcomes...
file:///var/folders/mw/0w9f93f97wscrp764dmz0k900000gp/T/com.apple.iChat/Messages/Transfers/IMG_6462.jpeg #ASH19 Image @mwschoen Dr. Schoen walks us through a hypothesis that renal impairment and racial differences in estimating renal function may impact treatment and outcome: 1) Pts with renal dies less likely to receive lenalidomide. Image
Dec 7, 2019 4 tweets 3 min read
Here's my #gerihemelist for #ASH19 Saturday... Abs 2209, Poster today: 1/3 of pts with "good" PS were frail; Frail pts with AML had 50% 100-day mortality! ash.confex.com/ash/2019/webpr…
Dec 7, 2019 5 tweets 4 min read
Abs 268: @HiraSMian presents data on >5700 pts with MM from Canadian registry with some good/some sobering news for #geriheme pts:
1. ASCT use rising
2. 60% of older pts get a novel drug
3. 20% 1-yr mortality
4. 30% of older patients received NO MYELOMA TREATMENT
#ASH19 Even with universal coverage, older pts, lower SES or more comorbidities less likely to be treated for myeloma #mmsm #geriheme #ASH19 ImageImage
Dec 7, 2019 4 tweets 3 min read
Abstract 67: all new patients with blood cancer age >=75 screened for frailty; participants randomized to receive geriatric consultation. Outcomes: feasibility, 1-yr OS, acute care utilization, goals of care discussion. ash.confex.com/ash/2019/webpr… 86% participated in RCT, but some patients worried that geriatric consultation would make them ineligible for treatment. Just heard this same observation from another #geriheme MD on the opposite side of the country just last night! @ROlinMD
Dec 2, 2019 9 tweets 8 min read
My top 8 #ASH19 #geriheme #myeloma abstracts.... 1. 2 out of 5 real-world myeloma patients ineligible for clinical trials; 75% of frail patients ineligible.
ash.confex.com/ash/2019/webpr…
#GeriHemeList
Nov 9, 2018 4 tweets 4 min read
A first step to honor @ArtiHurriaMD for her mentorship: The ASCO website is not currently enabled to allow us to nominate her, we may do so via email. Send the nomination with details below to grants@conquer.org with the Subject Line: WWCC Mentorship Award – D. Arti Hurria Image I've warned them that we will break their inbox. @WilliamDale_MD @rochgerionc @HKlepinMD @CPresGeriOncMD @DrJulieVose @MelissaLoh21 @melisawongmd @DrAllisonMags @WilliamTewMD @GrantWilliamsMD @smlichtman_md @efratdotan